| Literature DB >> 34017137 |
Erin M Bange1,2, Nicholas A Han1,3, Paul Wileyto2,4, Justin Y Kim1,3, Sigrid Gouma5, James Robinson2, Allison R Greenplate3,6, Madeline A Hwee7, Florence Porterfield1, Olutosin Owoyemi1, Karan Naik1, Cathy Zheng2, Michael Galantino2, Ariel R Weisman8, Caroline A G Ittner8, Emily M Kugler1, Amy E Baxter3,6, Olutwatosin Oniyide9, Roseline S Agyekum9, Thomas G Dunn9, Tiffanie K Jones9, Heather M Giannini8, Madison E Weirick5, Christopher M McAllister5, N Esther Babady10,11, Anita Kumar10, Adam J Widman10, Susan DeWolf10, Sawsan R Boutemine10, Charlotte Roberts2, Krista R Budzik2, Susan Tollett2, Carla Wright2, Tara Perloff2,12, Lova Sun1,2, Divij Mathew3,6, Josephine R Giles3,6,13, Derek A Oldridge3,14, Jennifer E Wu3,6,13, Cécile Alanio3,6,13, Sharon Adamski3,6, Alfred L Garfall1,2, Laura A Vella15, Samuel J Kerr2,16, Justine V Cohen2,12, Randall A Oyer2,16, Ryan Massa1,2,9, Ivan P Maillard1,2, Kara N Maxwell1,2, John P Reilly8, Peter G Maslak10,11, Robert H Vonderheide2,3,13, Jedd D Wolchok7,10,13, Scott E Hensley3,5, E John Wherry3,6,13, Nuala J Meyer3,8, Angela M DeMichele1,2, Santosha A Vardhana17,18,19, Ronac Mamtani20,21, Alexander C Huang22,23,24,25.
Abstract
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hematologic cancer had higher mortality relative to patients with solid cancer. In two additional cohorts, flow cytometric and serologic analyses demonstrated that patients with solid cancer and patients without cancer had a similar immune phenotype during acute COVID-19, whereas patients with hematologic cancer had impairment of B cells and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses. Despite the impaired humoral immunity and high mortality in patients with hematologic cancer who also have COVID-19, those with a greater number of CD8 T cells had improved survival, including those treated with anti-CD20 therapy. Furthermore, 77% of patients with hematologic cancer had detectable SARS-CoV-2-specific T cell responses. Thus, CD8 T cells might influence recovery from COVID-19 when humoral immunity is deficient. These observations suggest that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34017137 PMCID： PMC8291091 DOI： 10.1038/s41591-021-01386-7
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 87.241